News | October 27, 2014

Minimally Invasive Procedures Offer Hope for Elderly Patients with Heart-Valve Problems

TAVR proves effective for patients at University of Texas Southwestern Medical Center

Werner Dyer, who is now 92, had his TAVR last year and was able to rejoin his bowling league and now bowls four times a week.

October 27, 2014 – Annie Henderson, 69, suffers from multiple chronic ailments, including kidney failure and mitral valve insufficiency. The latter turned her life into a battle for breath, eliminating almost all activities and even making sleep a struggle. She couldn’t sleep for more than 20 minutes at a time without waking in a fit of coughing. Thanks to a leading-edge procedure performed at University of Texas (UT) Southwestern Medical Center, Mrs. Henderson is now breathing – and sleeping – easy.

UT Southwestern physicians perform two types of minimally invasive valve-repair procedures that offer hope for patients like Mrs. Henderson, who have incapacitating heart-valve problems but are too frail to undergo the rigors of open-heart surgeries. 

Transcatheter aortic valve replacement (TAVR) is used to replace a critically narrowed aortic valve, the valve between the heart and the main artery in the body. TAVR patients’ narrowed aortic valves prevent sufficient blood flow. The TAVR procedure is a less invasive treatment, alleviating the narrowing without the need for open-heart surgery.

The procedure involving the MitraClip device repairs a valve between the upper and lower chambers of the left side of the heart, called the mitral valve. This valve may not close fully, causing blood to flow backward into the left atrium and lungs. The MitraClip pinches the two leafs of the mitral valve together in the center so there is less backflow of blood.

Both procedures are performed by snaking catheters, typically from a blood vessel in the groin, up to the diseased valve. Patients may experience immediate improvement, and since the only incision is a small one to allow access to the blood vessel, recovery time is short.

This summer, UT Southwestern physicians performed their 50th TAVR procedure and, recently, Sarah Gualano, M.D., assistant professor of internal medicine and medical director of the Cardiac Catheterization Laboratory, with Michael Luna, M.D., assistant professor of internal medicine, performed the first MitraClip procedures. Mrs. Henderson was one of the first MitraClip patients.   

Gualano said she has seen patients whose lives had become restricted because of their heart-valve problems re-emerging into a wider world after their procedures.

“I had a patient in his 90s who could barely walk a block, doing calisthenics in his room after his TAVR procedure. Werner Dyer, who is now 92, had his TAVR last year and was able to rejoin his bowling league and now bowls four times a week.”

“It boils down to the simple fact that these patients had no options, and now we can make them feel better and, in the case of TAVR, live longer,” said Gualano.

Demographics mean these procedures will be increasingly important in the coming years.

“We have an aging population. As people age, they become very high-risk for open-heart surgeries,” said Steven Marso, M.D., medical director of interventional cardiology and professor of internal medicine. “People who wouldn’t have had an option for treatment now have an option for treatment,” he said.

Sitting in her hospital room 36 hours after her MitraClip procedure, Mrs. Henderson was beaming. Breathing is the easy process it should be once again, and there had been no coughing the previous night. “I didn’t wake up until the nurse woke me this morning,” Mrs. Henderson said happily.

For more information: www.utsouthwestern.edu

Related Content

National Survey Of Heart Valve Patients Shows Importance Of Seeking Treatment Early
News | Heart Valve Technology | August 12, 2020
August 12, 2020 — A national survey conducted by the patient advocacy group...
CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.

CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.

News | Heart Valve Technology | August 05, 2020
August 5, 2020 – Minneapolis-based CardioMech AS, a medical device company developing a transfemoral, transseptally d
The Edwards Konect Resilia aortic valved conduit (AVC).
News | Heart Valve Technology | July 15, 2020
July 15, 2020 —  The U.S. Food and Drug Administration (FDA) granted clearance for the Edwards Lifesciences Corp.
The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.
Key TAVR Takeaways From ACC 2020
Feature | Heart Valve Technology | April 20, 2020 | Dave Fornell, Editor
Some U.S.